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Abstract: Introduction: The value of monitoring physiological parameters to predict chronic
obstructive pulmonary disease (COPD) exacerbations is controversial. A few studies have suggested
benefit from domiciliary monitoring of vital signs, and/or lung function but there is no existing
systematic review. Objectives: To conduct a systematic review of the effectiveness of monitoring
physiological parameters to predict COPD exacerbation. Methods: An electronic systematic search
compliant with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines was conducted. The search was updated to April 6, 2016. Five databases were examined:
Medical Literature Analysis and Retrieval System Online, or MEDLARS Online (Medline), Excerpta
Medica dataBASE (Embase), Allied and Complementary Medicine Database (AMED), Cumulative
Index of Nursing and Allied Health Literature (CINAHL) and the Cochrane clinical trials database.
Results: Sixteen articles met the pre-specified inclusion criteria. Fifteen of these articules reported
positive results in predicting COPD exacerbation via monitoring of physiological parameters. Nine
studies showed a reduction in peripheral oxygen saturation (SpO2%) prior to exacerbation onset.
Three studies for peak flow, and two studies for respiratory rate reported a significant variation
prior to or at exacerbation onset. A particular challenge is accounting for baseline heterogeneity
in parameters between patients. Conclusion: There is currently insufficient information on how
physiological parameters vary prior to exacerbation to support routine domiciliary monitoring for
the prediction of exacerbations in COPD. However, the method remains promising.
Keywords: COPD; exacerbation; physiological signs; vital signs; lung function; home
monitoring; telehealth
1. Introduction
Chronic obstructive pulmonary disease (COPD) is a serious health matter, which significantly
impacts the individual’s quality of life. According to the World Health Organisation, in 2004, 65 million
people were diagnosed with COPD globally [1]. In 2012, three million people died because of COPD [2],
and thus COPD is anticipated to be the third leading cause of death by 2020 if no action is taken [3].
COPD, even when optimally managed, is associated with periodic deteriorations in respiratory health
called exacerbations. Exacerbations are defined in the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) document “as an acute event characterised by a worsening of the patient’s respiratory
symptoms that is beyond normal day-to-day variations and leads to a change in medication” [4]. Exacerbations
can lead to decline in the patient’s overall function, causing hospitalisation, and/or death. Therefore,
health care facilities, societies, and individuals have a common interest in better understanding how to
prevent and manage exacerbations, reduce disease progression, and support patient self-management.
To achieve this, early detection of exacerbations and prompt access to therapy and health services are
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needed. Detecting COPD exacerbation earlier will allow prompt initiation of treatment [4]; therefore
facilitating faster recovery and outcomes. This may result in a reduced number of hospital admissions,
and as well as a reduction in healthcare consumption.
It is recognised that whilst defined by changes in symptoms, exacerbations are also associated
with alterations in physiological variables. In 2010, Hurst et al. [5] examined the ability of domiciliary
pulse oximetry and peak flow to distinguish exacerbations from day to day fluctuations. They
reported that changes in heart rate, peripheral oxygen saturation (SpO2%), and peak flow were
significantly different just before and during an exacerbation. Rapid advancement in technology has
offered numerous solutions targeting the management of chronic diseases (collectively known as
tele-health). Tele-health is a form of distance communication between the patient and the healthcare
provider for monitoring, communicating, managing or facilitating intervention [6]. Tele-health may
monitor symptoms, and/or physiology parameters. Tele-health has shown some success in chronic
disease management. The PROMETE study conducted in 2014 in Spain by Segrelles et al. reported a
reduction in acute noninvasive ventilation (NIV) usage (p < 0.0001), emergency department (ER) visits
(p = 0.001), admissions (p = 0.015) and bed days (p = 0.018) [7]. More recent studies in COPD have not
been positive [8], perhaps reflecting the heterogeneity of COPD.
The objective of this systematic review was to summarise and report the value of domiciliary
physiological monitoring in predicting exacerbations in patients with COPD.
2. Methods
2.1. Search Strategy
This systematic review (PROSPERO registration CRD42016046643) is compliant with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards [9]. The search
was completed up to April 6, 2016. The search was performed in Medical Literature Analysis and
Retrieval System Online, or MEDLARS Online (Medline), Excerpta Medica dataBASE (Embase), Allied
and Complementary Medicine Database (AMED), Cumulative Index of Nursing and Allied Health
Literature (CINAHL), and the Cochrane clinical trials database. The search terms used are detailed in
the Appendix A, Tables A1 and A2. In addition to the electronic database search, the reference list of
eligible articles was also screened.
2.2. Inclusion Criteria
The studies included in this review met the following criteria: (1) Stable COPD; (2) Domiciliary
monitoring; (3) Monitoring any physiological variables; (4) Reporting statistical analysis of the
measured physiological variables; (5) Prediction of exacerbations via physiological variables.
2.3. Exclusion Criteria
We excluded the following: (1) Books; (2) Systematic reviews; (3) Non-English manuscripts;
(4) Conference abstracts with no full-text; (5) Non-full text articles.
The main outcome of interest was variation in physiological parameters before and during
COPD exacerbations, and the ability of measuring changes in physiological variables to provide early
detection of COPD exacerbations.
2.4. Data Collection
Screening of the titles and abstracts was performed by the first author to eliminate all non-relevant
studies. Titles and abstracts potentially relevant were read in full-text to evaluate if they were eligible
or not. In addition to screening and evaluating for eligibility, the reference list of the eligible articles
was screened. The second author confirmed the eligibility. Disagreement on five studies between
authors was resolved after discussion.
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2.5. Quality Assessment
The quality assessment was performed by each author individually based on two different
modified scales, the Cochrane tool [10] and Newcastle-Ottawa scale [11]. The Cochrane quality
assessment tool consists of seven questions to evaluate randomised studies included in this review.
The Newcastle-Ottawa scale consists of seven questions used to assess cohort and non-randomised
studies included in this review. The assessment was performed by each author individually and any
disagreement was solved by discussion.
2.6. Synthesis of Results
The primary purpose of this systematic review was to assess the feasibility of predicting
COPD exacerbations by domiciliary monitoring of physiological parameters. Because of significant
methodological heterogeneity between included studies, meta-analysis was not conducted. However,
a narrative synthesis of the results of the studies was performed and full details of the included studies
are reported in Tables 1 and 2.
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Table 1. Detailed description of the 16 included studies.
Author Subjects andCOPD Severity Country Measures Quality Detailed Description Results
Seemungal et al., 2000
[12] N = 101 severe COPD United Kingdom
PEFR
FEV1 Symptoms
Moderate quality
Period: 2.5 years.
PEFR and symptoms measured
daily, post morning medication.
In a subgroup of 34, FEV1 was
measured
Analysis of 504 exacerbations:
Lung function changed significantly on
the day of onset (p < 0.001). A decrease
in the median of:
PEFR by 8.6 L/m
FEV1: 24.0 mL
FVC: 76.0 mL
Cooper et al., 2009 [13] N = 19 mild−severeCOPD United Kingdom
HR
SpO2%
PEFR
FEV1 Symptoms
High risk of bias
Period: 4 months.
Participants measured their
vital signs and recorded their
symptoms twice a week in the
morning
Analysis of four exacerbations:
Concluded that SpO2% was the variable
most closely associated with
exacerbation but no statistical
significance reported
Sund et al., 2009 [14] N = 18 severe COPD United Kingdom FEV1 Symptoms Low quality
Period: 6 months.
Daily electronic diary and
performed three spirometry
manoeuvres daily in the
evening
Analysis of 75 exacerbations:
55 exacerbations were detected via
tele-health (symptoms) and 6/55
exacerbations were detected via FEV1
alone (p = not significant).
Exacerbation detected via FEV1 was
defined as a 10% fall in FEV1 for ≥2
consecutive days.
Hurst et al., 2010 [5] N = 31 severe COPD United Kingdom
HR
SpO2%
PEFR Symptoms
Moderate quality Period: 9 months.Daily paper diary cards
Analysis of 13 exacerbations:
Variation was noted prior and during
the onset of exacerbation in PEFR, HR,
and SpO2%.
Maximal change in SpO2% and HR
occurred two days into exacerbation:
SpO2% had fallen by −1.24 SD, HR
increased by +3.09 SD.
Maximal change in PEFR occurred four
days into exacerbation: −2.97SD
Composite Score to detect exacerbation:
AUC = 0.832, p < 0.05.
Jensen et al. in 2012 [15]
N = 57
moderate−severe
COPD
Denmark
HR
SpO2%
BP
Moderate quality Period: 4 months.Daily diary cards
Analysis of 9 exacerbations:
Their algorithm classified variables into
273 features and was able to detect seven
exacerbations via vital signs with 70%
sensitivity, 95% specificity, AUC = 0.73.
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Table 1. Cont.
Author Subjects andCOPD Severity Country Measures Quality Detailed Description Results
Berge et al., 2012 [16] N = 137 severe COPD Netherlands Salbutamol usePEFR Symptoms Moderate quality
Period: 15 months.
Daily diary cards
Analysis of 101 exacerbations:
Significant decrease in PEFR 15 L/min
at exacerbation compared to baseline.
Yanez et al. in 2012 [17] N = 89 severe COPD(On O2 therapy)
Spain Respiratory Rate (RR) Moderate quality
Period: 3 months.
Daily monitoring of respiratory
rate, using a sensor inserted
into the domiciliary oxygen
supply system
Analysis of 10 exacerbations:
Increase in the mean respiratory rate in
21/30 exacerbations, 1–5 days prior to
hospitalisation
Mean of respiratory rate raised:
Five days: 15.2 ± 4.3 min−1 to
19.1 ± 5.9 min−1
Two days: 2.3 min−1 (15% from baseline)
One day: 4.4 min−1 (30% from baseline)
All p-value < 0.05
Martin Lesende et al.
2013 [18]
N = 58 Heart failure
(27.6%) + O2 therapy
(57.1%) +
moderate−very
severe COPD and
asthma 25.9%
Spain
HR
SpO2%
BP
RR
Weight
Temperature
Symptoms
High risk of bias Period: 12 months.Daily monitoring
In the five days preceding hospital
admission:
Mean SpO2% fell from 93.1% to 91.0%
(4.6 SD), and mean HR increased from
77.8 to 84.2 min−1 (17.1 SD) p = 0.003 for
both. No significant change for
respiratory rate, body temperature and
blood pressure.
Pedone et al. 2013 [19]
N = 99
moderate−severe
COPD
Italy
HR
SpO2%
TemperaturePhysical
activity
High risk of bias
Period: 9 months.
Automatic recording of vital
signs, a mean of four times
per day.
Analysis of 13 exacerbations:
SpO2% fell three days before an
exacerbation, which permitted timely
intervention, and was associated with a
33% reduction in hospitalisation rate
(p = not shown, data displayed in a
Figure only).
Segrelles et al., 2014 [7] N = 60 severe COPD(On O2 therapy)
Spain
HR
SpO2%
BP
PEFR
High risk of bias
Period: 7 months.
Participants monitored their
vital signs every morning, but
PEFR was three times/week.
Analysis of 50 red flags: confirmed red
flag defined as moderate, severe or very
severe exacerbation.
Tele-health was associated with
significant reduction in acute NIV usage
(p < 0.0001), ER visits (p = 0.001),
admissions (p = 0.015) and bed days
(p = 0.018). Reported that SpO2% and
PEFR were the most predictive
parameters (but data not reported).
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Table 1. Cont.
Author Subjects andCOPD Severity Country Measures Quality Detailed Description Results
Harding et al., 2015 [20]
N = 18
moderate−very
severe COPD
United Kingdom
HR
SpO2%
Symptoms
Moderate quality
Period: 6 months.
Each participant asked to fill a
daily symptom diary card.
Analysis of 37 exacerbations:
15/37 exacerbations were identified in three
days prior to medication self-initiation.Alerts
related to events: 47 symptom alerts
(16 patients) 80 HR alerts (18 patients), and
62 SpO2% alerts (17 patients). p = not shown.
Mohktar et al., 2015 [21]
N = 21
moderate−very
severe COPD
Australia
HR
SpO2%
BP
RR
Weight
Temperature
FEV1 Symptoms
Moderate quality
Period: 11 months.
Participants daily monitored
their vital signs and symptoms
Analysis of 90 exacerbations:
The designed algorithm identified 55/90 true
exacerbations (71.8% sensitivity 80.4%
specificity). FEV1 value (k = 0.21), mean of
distribution of SpO2% (k = 0.27) and the weight
(k = 0.21) were the most predictive variables
(p = not shown).
Fernandez-Granero et al.,
2015 [22]
N = 16
severe−moderate
COPD
Spain Respiratory sound Moderate quality
Period: 6 months.
Daily recorded respiratory
sounds using a microphone
over the super-sternal notch
Analysis of 33 exacerbations:
25 out of 33 exacerbations were detected 5 ± 1.9
days prior to the onset of exacerbation by
changes in sounds (p = not shown).
Burton et al., 2015 [23] N = 33 mild−verysevere COPD United Kingdom
HR
SpO2%
FEV1
PEFR Symptoms
Moderate quality
Period: >200 days.
Each participant asked to fill a
symptom questionnaire, and
measure heart rate, and SpO2%
daily. FEV1 and PEFR
monitored weekly.
Analysis of 172 exacerbations:
Increase in HR (87 min−1–94 min−1) at the
onset of exacerbation and mean SpO2% fell
(93.6% to 92.4%) around the onset of
exacerbation. Exacerbation associated with a
reduction of 0.1 L in FEV1.
Borel et al., 2015 [24]
N = 44 severe COPD
(On NIV and O2
therapy)
France
RR
%Triggering
NIV usage
Questionnaire
Moderate quality
Period: 6 months.
Daily monitoring via the
ventilator and daily
EXACT-Pro questionnaire.
Analysis of 21 exacerbations:
21 exacerbations detected, and the risk of
exacerbation was high if high value noted on ≥
two days out of five for RR P = 0.01, and
%Triggered Breaths p = 0.037, but not total NIV
usage p = 0.097).
Hamad et al., 2016 [25] N = 183 COPD * United Kingdom
HR
SpO2%
Temperature
Physical activity
Symptoms
Moderate quality Period: 4 months.Daily monitoring.
Analysis of 98 exacerbations:
80/98 showed changes on one or more
tele-health parameters prior to
hospitalisation/exacerbation onset.
30 exacerbations resulted in hospitalisation and
7/30 had significant SpO2% reduction
(significant defined for each patient
individually, p = 0.049)
12/98 exacerbations had a significant SpO2%
fall (p < 0.05).
* Disease severity not reported. COPD: chronic obstructive pulmonary disease; FVC: forced vital capacity; PEFR: peak expiratory flow rate; FEV1 forced expiratory volume in one
second; HR: heart rate; SpO2%: peripheral capillary oxygen saturation; BP: blood pressure; RR: respiratory rate; NIV: noninvasive ventilation; EXACT: exacerbations of chronic
pulmonary disease tool; Pro: Patient-reported outcome; SD: standard deviation; AUC: area under the curve.
J. Clin. Med. 2016, 5, 108 7 of 18
Table 2. Detailed description of the 16 included studies.
Author Definition of Exacerbation
Seemungal et al., 2000 [12] Anthonisen criteria.
Cooper et al., 2009 [13] Not explained.
Sund et al., 2009 [14] Increase of two symptoms and/or ≥10% reduction of FEV1 for ≥2consecutive days; or the use of antibiotics and/or prednisolone.
Hurst et al., 2010 [5] ≥2 of new or worsening symptoms (one should be increasedbreathlessness, sputum volume of sputum purulence) for ≥2 days.
Jensen et al. in 2012 [15] Admission to hospital, or started antibiotics or steroids withspecific symptoms.
Berge et al., 2012 [16] Not explained.
Yanez et al., 2012 [17] Clinical diagnosis by an emergency room clinician.
Martin Lesende et al., 2013 [18] Not explained.
Pedone et al., 2013 [19] Change in symptoms that lead to a change in medication.
Segrelles et al., 2014 [7] GOLD definition.
Harding et al., 2015 [20] Initiation of antibiotics or steroids or both.
Mohktar et al., 2015 [21] GOLD definition.
Fernandez-Granero et al., 2015 [22] Use of medication for exacerbation, and/or unplanned emergencyroom visits and/or hospital admissions.
Burton et al., 2015 [23] Anthonisen criteria or started antibiotics.
Borel et al., 2015 [24]
If abnormal values of respiratory rate and % triggered breaths were
reported for two days or more, or abnormal values of NIV daily usage
were reported for three days or more out of five.
Abnormal values were defined as “value of a parameter was >75th or
<25th percentile, the day was recorded as abnormal value’
(‘high value’ > 75th, ‘low value’ < 25th).
Hamad et al., 2016 [25] Admission to hospital, or started antibiotics or/and steroids.
3. Results
The systematic review search generated 3377 articles, 345 were excluded due to duplication. After
screening the titles and abstracts, 28 articles out of 3032 were potentially relevant to the inclusion
criteria. After that, full-text screening of the 28 articles was conducted to assess eligibility, which
resulted in 13 relevant articles. The reference list of the relevant articles was also examined which
resulted in identification of three further articles giving 16 in total (Figure 1).
Of the 16 articles that met the pre-specified inclusion criteria, all the studies were conducted
prospectively, and in seven different countries: one each in Australia, Denmark, France, Italy,
Netherlands, four in Spain, and eight in the United Kingdom. Most of the articles were published in
2015 (5/16), with three in 2012, two each in 2009 and 2013, and one each was published in 2000, 2010,
2014 and 2016. The sample size and duration of the studies varied from three months to fifteen months
except for one study, which was run for 30 months. The sample size varied from 16 to 183 participants
(eight studies <50 patients, five studies ≥50 patients, and three studies >100 patients). Fifteen studies
were on COPD patients only (at different disease stages), and one was on heart failure and chronic
lung disease patients [16]. Full details of the included studies are reported in Tables 1 and 2.
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Quality Assessment
Among the 16 identified articles, four studies were randomised clinical trials and 12 were cohort
studies. The four studies evaluated using the modified Cochrane risk of bias tool [10] were ranked as
being at high risk of bias. The 12 studies evaluated by the modified Newcastle-Ottawa scale [11] were
all ranked as moderate quality except for one, which was ranked as low quality.
4. Monitoring Vital Signs to Predict Exacerbation
4.1. He rt Rate and Oxygen Saturation
Most of the included studies 14/16 monitored the participant’s vital signs and assessed the
capability of vital signs to predict COPD exacerbation. Although heart rate (HR) and oxygen saturation
(SpO2%) were monitored in 10/16 studies [5,7,13,15,18–21,23,25], 7/10 studies did not report any
statistical analysis for the HR and SpO2% variation. However, they concluded with the possibility that
heart rate and/or SpO2% may be useful in detecting deterioration. Four studies (three at moderate
quality, and one at high risk of bias) reported a significant variation (p ≤ 0.05) in HR and/or SpO2%
prior to the onset of COPD exacerbation [5,18,23,25]. In Hurst et al. [5], the magnitude of the fall in
SpO2% two days into the exacerbation was −1.24 standard deviation (SD) and the rise in HR was
+3.09 SD above the patient’s baseline. Martin-Lesende et al. [18] reported the difference between the
mean values monitored over the whole study period, which were for SpO2% 93.1% (2.2 SD), and for HR
77.8 min−1 (14.6 SD); Moreover, the mean values monitored over the five days prior to cause-specific
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admission were for SpO2% 91.0% (4.6 SD) and for HR 84.2 min−1 (17.1 SD), p = 0.003 for both. There
was therefore a typical rise in HR of 7 min−1 and fall in SpO2% of 2%. Burton et al. [23] reported that
the magnitude of SpO2% fall and HR rise was approximately 1 SD (SpO2% fall from 93.6% to 92.4%,
and HR increased from 87.4 min−1 to 93.7 min−1).
4.2. Respiratory Rate
The works of Yanez and Borel, which were ranked as moderate quality [17,24], evaluated
variations in respiratory rate prior to an exacerbation. In both, the change was statistically significant
(p ≤ 0.05). Importantly Yanez et al. reported an increase in the mean respiratory rate one to five days
prior to hospitalisation due to an acute exacerbation. At 48 h, the mean respiratory rate increased
by 2.3 min−1 (15% from baseline) with 72% sensitivity and 77% specificity (area under the curve
(AUC) = 0.76, p < 0.05) for detecting exacerbation, whilst the rise noted 24 h prior to hospitalisation
at 4.4 min−1 (30% from baseline) had a 66% sensitivity and 93% specificity (AUC = 0.79, p < 0.05) for
exacerbation detection. At five days before hospitalisation, the mean respiratory rate rose from
15.2 ± 4.3 min−1 to 19.1 ± 5.9 min−1 (p < 0.05) suggesting a longer window for preventing
hospitalisation. However, in contrast, Martin Lesende [18] did not see significant change in the
respiratory rate five days before hospitalisation. Mohktar [21] included respiratory rate with daily
monitored variables, but no analysis was reported.
4.3. Blood Pressure and Temperature
Four studies of 16 (two at high risk of bias and two at moderate quality) included blood
pressure monitoring [7,15,18,21], but there was no evidence indicating changes in blood pressure
was as a variable with high predictive capacity for exacerbation (p-value not significant). Likewise,
body-temperature was monitored in 4 out of of 16 studies. Martin-Lesende [18] compared the mean
temperature in the overall follow-up period, 35.9 ◦C (0.4SD), to the mean of five days, 35.5 ◦C
(1 SD), prior to cause-specific admission. Changes in body temperature resulted in 27.8% of alerts
(only 5.6% of alerts were due to an increased temperature over 37 ◦C). Hamad [25] reported increased
body-temperature in 9 out of 98 exacerbations.
Five studies (two at high risk of bias and three at moderate quality) out of 16 [13,15,19,20,22] did
not provide sufficient statistical analysis of changes in vital signs despite reporting these variables. For
example, Pedone [19] evaluated the capability of a tele-monitoring system for lower hospitalisation
rates, and to identify COPD exacerbation onset. The researchers did not report whether the result was
statistically significant but noted a 33% reduction in the risk of hospitalisation. Pedone also noted a
fall in SpO2% in three days preceding the onset of an exacerbation, which therefore led to prediction of
COPD exacerbation. Furthermore, Jensen [15] tried to develop an algorithm to enhance the prediction
of COPD exacerbation. The four variables heart rate, systolic blood pressure, diastolic blood pressure,
and oxygen saturation were monitored and classified into 273 features. Jensen reported that their
system was able to distinguish ten COPD exacerbations with 70% sensitivity, 95% specificity, and
0.73 AUC.
Considered together, SpO2% was the most studied variable before an exacerbation episode, and
the variable which has been reported to have the highest predictive capacity although the magnitude
of change is typically small (1%–2%).
5. Monitoring Lung Function to Predict Exacerbations
Lung function, particularly spirometry, is a valuable test for diagnosing COPD and evaluating
disease progression. A few studies assessed the usefulness of lung function variables in predicting
acute exacerbation. Eight studies (two at high risk of bias, one as low quality, and two at moderate
quality) of 16 [5,7,12–14,16,21,23] monitored either the peak expiratory flow rate (PEFR), or the forced
expiratory volume in one second (FEV1), or both. Three studies [12,13,23] measured FEV1 and PEFR at
different frequencies (per day/per week). Seemungal et al. [12] reported data from 101 COPD patients
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on PEFR, FEV1 and vital capacity (FVC) on the day of exacerbation onset, and showed significant
changes (p < 0.001). The analysis of 504 COPD exacerbations revealed a fall in the median PEFR of 8.6
(interquartile range (IQR) 0 to 22.9) L/min, FVC of 76.0 (IQR −40.4 to 216.4) mL, and FEV1 of 24.0
(IQR −16.1 to 84.3) mL. Burton et al. [23] reported a strong correlation between FEV1 and PEFR and a
0.1 L reduction in FEV1 was associated with a change in the symptom score.
Sund et al. at low quality and Mohktar et al. at moderate quality [14,21] focused only on FEV1.
Sund [14] detected 55/75 exacerbations using monitoring, and 6/55 exacerbations were detected only
via FEV1 (defined as a 10% fall in FEV1 for ≥2 consecutive days). Three studies [5,7,16] examined
predicting COPD exacerbations with daily monitoring of PEFR. Segrelles [7] did not report detailed
PEFR data, but reported that PEFR and SpO2% were the most predictive variables. Hurst [5] reported
a statistically significant variation in PEFR before and during an acute exacerbation with a maximal
−2.97 SD fall in PEFR four days into the exacerbation. However, Berge [16] reported a significant
decrease in the mean of PEFR during an exacerbation episode, which was back to baseline in two weeks.
6. Monitoring Respiratory Sounds to Predict Exacerbations
In 2015 Fernandez-Granero at moderate quality [22] reported a study demonstrating that 25 out
of 33 COPD exacerbations could be detected via monitoring patient’s respiratory sounds at home.
Each participant was asked to record his/her respiratory sounds daily by placing a microphone on the
suprasternal notch. Exacerbation episodes were detected 5 ± 1.9 days prior to the exacerbation onset
with a sensitivity of 73.76% and 97.67% specificity.
7. Methodological Considerations
7.1. Alarm limits
A challenge in COPD is the variation between patients and how to set alarm limits for an
individual patient. Of the 16 articles included in this review, only eight studies (three at high risk
of bias, one at low quality and two at moderate quality) [5,13,14,18–21,25] mentioned that they had
customised the alarm limits for each individual. Methods used were reported in six out of the eight
studies. Cooper [13] monitored the participants for two weeks to identify the normal range for each
and personalise the alert limits. Sund [14] set a baseline for each participant by taking the median and
the mean after monitoring symptoms and FEV1 for 14 days (exacerbation-free). In the Hurst study [5],
heart rate, oxygen saturation, and peak expiratory flow rate assessed for 30 days (symptom-free).
These established a baseline of the selected variables with ±SD. Pedone [19] customised the limits
based on the participant’s “clinical situation”. Harding [20] personalised each participant’s limits
by applying a probability density function after monitoring the participant for six weeks, or having
40 sets of recorded daily data. Mokhtar [21] personalised the limits range in a different way; they took
the median (50th percentile), lower (25th percentile), and upper (75th percentile). They then adjusted
the lower limits to be 25th percentile minus 1.5 times the interquartile, and the upper limits to be 75th
percentile plus the 1.5 times the interquartile. There are no studies comparing different methods of
personalising alarm limits.
7.2. Monitoring Characteristics
The approach pursued by the 16 studies in monitoring physiological signs were heterogeneous
with regard to the type of equipment or instrument used to monitor and assess the participant’s
data. In some studies, a mobile/tablet app was used to communicate with the participant [19,20],
and transfer data. Some studies set up a monitoring station for each individual with different
devices [7,13–15,17–19,21–25], where the data were transmitted automatically through an Internet
modem. If a red flag was raised or threshold breached, a notification alert was sent to the system
operator in real time. In two other studies, another form of monitoring was used. A diary card
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for symptoms and vitals were provided to participants, and a visit was arranged to collect the
data [5,12,16].
7.3. Intermittent vs. Continuous Monitoring
In the reviewed articles, 16 studies monitored the participants’ physiological parameters and
symptoms intermittently. The frequency of monitoring/recording was varied, some once daily or
multiple times daily. However, in four studies [7,13,14,23], participant’s data were monitored less
than daily (different frequencies per week). In addition to that, sometimes measurements taken were
restricted to morning, however, in Harding et al. [20], the stipulated time for measurements recording
was based on the patient’s preference.
8. Discussion
We have conducted the first systematic review examining the utility of monitoring physiological
variables to predict exacerbations of COPD. In general, and as discussed below, the studies are small
and heterogeneous using different variables and different protocols. The need for better healthcare
solutions in people diagnosed with chronic diseases is real. COPD imposes burdens on individuals
and health care organisations. Whilst the methods hold promise, further adequately powered studies
are required to properly define the utility of physiological monitoring to predict exacerbations.
In this systematic review, sixteen articles met the inclusion criteria, which were compliant with
PRISMA. Five studies out of 16 [13,15,19,20,22] did not provide sufficient statistical data to draw
conclusions consistent with the results of other studies, despite reporting changes in physiological
variables (no p-value). The methodological quality of the studies was variable but generally low with
12 cohort studies ranked as moderate or low quality, and four trials ranked as having a high risk
of bias.
We have described those studies that showed positive results in predicting/detecting an
exacerbation episode via monitoring of physiological parameters. Although this approach appears
to be promising, further well-designed clinical trials are required to investigate the true magnitude
and time-course pre, during, and post an exacerbation episode of changes in physiological parameters.
Understanding the extent of the magnitude of change for each variable is critical in using this
knowledge for early exacerbation detection. In three studies [5,18,23] the magnitude of the change in
heart rate and SpO2% reported was an increase of around 5 min−1 for heart rate and a fall by 1%–2%
for SpO2%. Two studies [17,24] reported an increase in the respiratory rate before the onset of COPD
exacerbation/hospitalisation. These findings all support the hypothesis that monitoring of vital signs
can detect respiratory deterioration. However, the question arises as to whether these variables can
be reliable enough. Moreover, to answer that question we need to better understand the relationship
between physiological signs and symptoms. This has been confirmed in some of the above mentioned
studies [5,12,14]. Hurst combined peak expiratory flow (PEF) with a symptom score to provide optimal
exacerbation detection [5].
Having demonstrated that monitoring physiological variables has the theoretical potential
to detect COPD exacerbations, the second step is implementation of this in a clinical
environment—Tele-monitoring. To enable healthcare providers and patients to feel secure managing
COPD and detecting acute exacerbations with no anticipated harm, an intelligent interface to provide
live communication is essential. In the above mentioned studies, various designs were employed.
However, the optimal technique/algorithm still requires more investigation. Despite the fact that
tele-health offers the possibility for the clinician and the patient to be connected and monitored in
a ‘virtual clinic’, the accuracy and specificity of this discipline are still uncertain. Developing an
algorithm to detect an exacerbation is important because that would facilitate the services provided
via tele-health. A particular challenge is around alarm thresholds. To increase the value of tele-health
in self-management, a customised threshold for each patient is essential as this will help to decrease
false alarms, and differentiate between true deterioration and day-to-day variation. Six studies had
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addressed this issue by specifying the alarm settings for each individual [5,13,14,19–21], but using
different methods and the optimal way to set individual patient alarms remains an open question.
Even though most of the reviewed studies exhibited some significant positive results in the
efficacy of physiological parameters in predicting/detecting COPD exacerbation, there are insufficient
data to draw a secure conclusion in this review. This is due to the diversity of the designs, methods,
and sample size of studies. The demand for technology to meet the needs of the COPD patient and
society are increasing. Further clinical trials are needed to achieve that.
Strength and Limitations
In this systematic review, a number of limitations can be considered. First, non-English studies
(abstract and full text) were excluded. Second, only one author performed the screening of titles and
abstracts, which may have increased the risk that studies were excluded inappropriately. Thirdly,
the definitions of exacerbation vary across the studies, which can make comparison between studies
challenging. The major strength of this study is that, to our knowledge, there is no pre-existing review
conducted regarding the usefulness of monitoring physiological signs to predict COPD exacerbation.
9. Conclusions
Monitoring of physiological parameters may be useful in assisting earlier detection of COPD
exacerbations but further, robust studies are required to confirm this. A particular challenge is
how to set alarm limits for individual patients given the heterogeneity inherent in COPD and
COPD exacerbations.
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Appendix
Table A1. Medline Search Strategy.
1 lung diseases, obstructive/ or exp. bronchitis/ or exp. pulmonarydisease, chronic obstructive/ 84,036 Advanced Display Results More
2 emphysema$.mp. 31,994 Advanced Display Results More
3 bronchiti$.mp. 30,780 Advanced Display Results More
4 (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$or respirat$)).mp. 96,121 Advanced Display Results More
5
(copd or coad or cobd or aecb).mp. [mp = title, abstract, original title,
name of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
33,479 Advanced Display Results More
6 1 or 2 or 3 or 4 or 5 153,864 Advanced Display Results More
7 telemedicine/ or telerehabilitation/ 14,118 Advanced Display Results More
8
(telemonitor* or tele-monitor* or tele-health* or telehealth* or
telemedicine or tele-medicine or tele-rehabilitat* or telerehabilitat*).mp.
[mp = title, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word,
unique identifier]
18,772 Advanced Display Results More
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Table A1. Cont.
9
(e-health or ehealth or m-health or mhealth or mobile health).mp.
[mp = title, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word,
unique identifier]
8219 Advanced Display Results More
10 exp. Telemetry/ 10,614 Advanced Display Results More
11
(telemetr* or tele-metr*).mp. [mp = title, abstract, original title, name of
substance word, subject heading word, keyword heading word,
protocol supplementary concept word, rare disease supplementary
concept word, unique identifier]
12,888 Advanced Display Results More
12 Monitoring, Ambulatory/ 6635 Advanced Display Results More
13
(monitoring adj4 (ambulatory or home$)).mp. [mp = title, abstract,
original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
23,156 Advanced Display Results More
14 Domiciliary.mp. 2364 Advanced Display Results More
15 software/ or mobile applications/ or user-computer interface/ 114,192 Advanced Display Results More
16
(software* or app? or iphone or ipad or android or smartphone* or
smart-phone*).mp. [mp = title, abstract, original title, name of
substance word, subject heading word, keyword heading word,
protocol supplementary concept word, rare disease supplementary
concept word, unique identifier]
205,344 Advanced Display Results More
17 or/7–16 284,600 Advanced Display Results More
18
(exacerbat* or deteriorat*).mp. [mp = title, abstract, original title, name
of substance word, subject heading word, keyword heading word,
protocol supplementary concept word, rare disease supplementary
concept word, unique identifier]
176,862 Advanced Display Results More
19 heart rate/ 149,127 Advanced Display Results More
20 Pulse/ 16,765 Advanced Display Results More
21 ((heart* or pulse* or cardiac) adj3 rate*).mp. 229,964 Advanced Display Results More
22 respiratory rate/ or Respiration/ 75,932 Advanced Display Results More
23
((respirat* or breath*) adj3 rate*).mp. [mp = title, abstract, original title,
name of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
24,774 Advanced Display Results More
24 exp. Oximetry/ 13,116 Advanced Display Results More
25 oximetr*.mp. 15,161 Advanced Display Results More
26 Oxygen/ 150,124 Advanced Display Results More
27 SPO2.mp. 3207 Advanced Display Results More
28 oxygen.mp. 519,842 Advanced Display Results More
29
(physiological adj4 (variable* or measure*)).mp. [mp = title, abstract,
original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
10,547 Advanced Display Results More
30 early diagnosis/ 19,913 Advanced Display Results More
31
(early adj4 (detect* or diagnos*)).mp. [mp = title, abstract, original title,
name of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
176,122 Advanced Display Results More
32
predict*.mp. [mp = title, abstract, original title, name of substance
word, subject heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept
word, unique identifier]
1,238,846 Advanced Display Results More
33 or/18–32 2,291,354 Advanced Display Results More
34 6 and 17 and 33 795 Advanced
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Table A2. Database Search Strategy.
Database Subject Heading Keyword
Medline
lung diseases, obstructive/ or exp. bronchitis/ or exp.
pulmonary disease, chronic obstructive/
telemedicine/ or telerehabilitation/
exp. Telemetry/
Monitoring, Ambulatory/
software/ or mobile applications/ or user-computer
interface/
heart rate/
Pulse/
respiratory rate/ or Respiration/
exp. Oximetry/
Oxygen/
early diagnosis/
emphysema$.
bronchiti$.
(obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$
or bronch$ or respirat$)).
(copd or coad or cobd or aecb)
(telemonitor* or tele-monitor* or tele-health* or telehealth*
or telemedicine or tele-medicine or tele-rehabilitat* or
telerehabilitat*)
(telemetr* or tele-metr*)
(monitoring adj4 (ambulatory or home$)).
Domiciliary.
(software* or app? or iphone or ipad or android or
smartphone* or smart-phone*).
(exacerbat* or deteriorat*).
((heart* or pulse* or cardiac) adj3 rate*).
((respirat* or breath*) adj3 rate*).
oximetr*.
SPO2.
oxygen.
(physiological adj4 (variable* or measure*)).
(early adj4 (detect* or diagnos*)).
predict*.
Embase
lung diseases, obstructive/ or exp. bronchitis/ or exp.
pulmonary disease, chronic obstructive/
exp. telemonitoring/ or exp. telemedicine/
telerehabilitation/
exp. telephone telemetry/ or exp. telemetry/
exp. ambulatory monitoring/
computer program/ or exp. communication software/
or exp. mobile application/
exp. computer interface/
heart rate variability/ or exp. heart rate/
exp. pulse rate/ or exp. “heart rate and rhythm”/
exp. breathing/ or exp. breathing rate/
exp. oximetry/ or exp. measurement/ or exp. pulse
oximetry/
exp. oxygen breathing/
exp. early diagnosis/
emphysema$.
bronchiti$.
(obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$
or bronch$ or respirat$)).
(copd or coad or cobd or aecb).
(telemonitor* or tele-health* or telehealth* or telemedicine or
tele-medicine or tele-monitor*).
(e-health or ehealth or m-health or mhealth or mobile health).
(telemetr* or tele-metr*).
((respirat* or breath*) adj3 rate*).
oximetr*.
SPO2.
Oxygen
(physiological adj4 (variable* or measure*)).
(early adj4 (detect* or diagnos*)).
predict*.
(monitoring adj4 (ambulatory or home$)).
Domiciliary.
(software* or app? or iphone or ipad or android or
smartphone* or smart-phone*).
(exacerbat* or deteriorat*).
((heart* or pulse* or cardiac) adj3 rate*).
AMED
pulmonary disease chronic obstructive/ or bronchitis/
or pulmonary emphysema/ or lung diseases
obstructive/
telemedicine/
home care services/
internet/ or exp. computers/ or software/
disease progression/
heart rate/
Pulse/
exp. Respiration/
Oxygen/
monitoring physiologic/ or respiratory function tests/
diagnosis/
emphysema$.
bronchiti$.
(obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$
or bronch$ or respirat$)).
(copd or coad or cobd or aecb).
(telemonitor* or tele-monitor* or tele-health* or telehealth*
or telemedicine or tele-medicine or tele-rehabilitat* or
telerehabilitat*).
(e-health or ehealth or m-health or mhealth or mobile health).
(telemetr* or tele-metr*).
((monitoring adj4 (ambulatory or home$)).
Domiciliary.
(software* or app? or iphone or ipad or android or
smartphone* or smart-phone*).
(exacerbat* or deteriorat*).
((heart* or pulse* or cardiac) adj3 rate*).
((respirat* or breath*) adj3 rate*).
oximetr*.
SPO2.
oxygen.
(physiological adj4 (variable* or measure*)).
(early adj4 (detect* or diagnos*)).
predict*.
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Table A2. Cont.
Database Subject Heading Keyword
CINAHL
(MH “Lung Diseases, Obstructive”) OR (MH
“Bronchitis+”) OR (MH “Emphysema”) OR (MH
“Pulmonary Disease, Chronic Obstructive+”)
(MH “Telenursing”) OR (MH “Telepathology”) OR (MH
“Remote Consultation”) OR (MH “Telemedicine”) OR
(MH “Telehealth”)
(MH “Telemetry”)
(MH “Ambulatory Care”)
(MH “Software”) OR (MH “Communications
Software+”) OR (MH “Mobile Applications”) OR (MH
“User-Computer Interface+”)
(MH “Pulse”) OR (MH “Heart Rate”)
(MH “Wireless Communications”) OR (MH
“Telephone+”) OR (MH “Instant Messaging”)
(MH “Respiratory Rate”) OR (MH “Respiratory Sounds”)
(MH “Respiration+”)
(MH “Oximetry+”)
(MH “Oximeters+”)
(MH “Oxygen”)
(MH “Oxygenation”) OR (MH “Oxygen Saturation”)
(MH “Monitoring, Physiologic”)
(MH “Early Diagnosis”)
TX emphysema*
TX bronchiti*
TX (copd or coad or cobd or aecb)
TX (obstruct* n3 (pulmonary or lung* or airway* or airflow*
or bronch* or respirat*))
TX (telemonitor* or tele-monitor* or tele-health* or
telehealth* or telemedicine or tele-medicine or
tele-rehabilitat* or telerehabilitat*)
TX (e-health or ehealth or m-health or mhealth or “mobile
health”)
TX (telemetr* or tele-metr*)
TX monitoring n4 (ambulatory or home*)
TX Domiciliary
TX (app# or iphone or ipad or android or smartphone* or
smart-phone*) OR TI software* OR AB software*
TX (exacerbat* or deteriorat*)
TX ((heart* or pulse* or cardiac) n3 rate*)
TX (respirat* or breath*) n3 rate*
TX oximetr*
TX SPO2
TX oxygen
TX (physiological n4 (variable* or measure*))
TX (early n4 (detect* or diagnos*))
TX predict*
Cochran
[mh “lung diseases, obstructive”]
[mh bronchitis]
[mh “pulmonary disease, chronic obstructive”]
[mh telemedicine]
[mh telerehabilitation]
[mh Telemetry]
[mh “Monitoring, Ambulatory”]
[mh software]
[mh “mobile applications”]
[mh “user-computer interface”]
[mh “heart rate”]
[mh pulse]
[mh “respiratory rate”]
[mh Respiration]
[mh Oximetry]
[mh Oxygen]
[mh “early diagnosis”]
COPD
emphysema*
bronchiti*
(obstruct* near/3 (pulmonary or lung* or airway* or airflow*
or bronch* or respirat*))
(copd or coad or cobd or aecb)
(telemonitor* or tele-monitor* or tele-health* or telehealth*
or telemedicine or tele-medicine or tele-rehabilitat* or
telerehabilitat*)
(e-health or ehealth or m-health or mhealth or mobile health)
(telemetr* or tele-metr*)
(monitoring near/4 (ambulatory or home*))
Domiciliary
(software* or app or apps or iphone or ipad or android or
smartphone* or smart-phone*)
(exacerbat* or deteriorat*)
((heart* or pulse* or cardiac) near/3 rate*)
((respirat* or breath*) near/3 rate*)
oximetr*
SPO2
Oxygen
(physiological near/4 (variable* or measure*))
(early near/4 (detect* or diagnos*))
predict*
Table A3. Excluded Studies.
First Author Study Title Reason
Malliopoulos, C., 2008 Continuous mobile services for healthcare:The health wear project
Article not available and no response from
the author
Antoniades, N.C., 2012 Pilot study of remote telemonitoring in COPD No physiological data shown and it does notaddress the prediction of COPD exacerbation
Jensen, M.H., 2012
Clinical impact of home telemonitoring on
patients with chronic obstructive pulmonary
disease
Not relevant (evaluated the impact of
tele-health on patients, not in predicting
exacerbation)
Jakobsen, A.S., 2013
Hospital-admitted COPD patients treated at
home using telemedicine technology in The
Virtual Hospital Trial: methods of a
randomized effectiveness trial
Recruited non-stable COPD patients for
preventing readmission
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Table A3. Cont.
First Author Study Title Reason
Jehn, M., 2013
Tele-monitoring reduces exacerbation of
COPD in the context of climate change-a
randomized controlled trial
Looked at the association between the
weather and exacerbation.
Pinnock, H., 2013
Effectiveness of telemonitoring integrated
into existing clinical services on hospital
admission for exacerbation of chronic
obstructive pulmonary disease: researcher
blind, multicentre, randomised controlled
trial
No physiological variation reported and not
for predicting exacerbation
San Miguel, K., 2013
Telehealth remote monitoring for
community-dwelling older adults with
chronic obstructive pulmonary disease
No physiological variation reported and not
for predicting exacerbation
Schou, Lone, 2013
A randomised trial of telemedicine-based
treatment versus conventional hospitalisation
in patients with severe COPD and
exacerbation—Effect on self-reported
outcome
Not for predicting exacerbation and recruited
non-stable COPD patients
van der Heijden, M., 2013 An autonomous mobile system for themanagement of COPD Designing a mobile system
Zhang, J., 2013
MIOTIC study: A prospective, multicenter,
randomized study to evaluate the long-term
efficacy of mobile phone-based internet of
things in the management of patients with
stable COPD
No physiological variation reported and not
for predicting exacerbation
Ding, H., 2014
A pilot study of a mobile-phone-based home
monitoring system to assist in, remote
interventions in cases of acute exacerbation
of COPD
Did not report any monitored physiological
data
Ko, F.W.S., 2014 COPD care programme can reducereadmissions and in-patient bed days Recruited non-stable COPD patients
Minami S., 2014
Ambulatory pulse oximetry monitoring in
Japanese COPD outpatients not receiving
oxygen therapy
Monitored the patient’s SPO2% for a 24 h
period only.
Jakobsen, A.S., 2015
Home-Based Telehealth Hospitalization for
Exacerbation of Chronic Obstructive
Pulmonary Disease: Findings from “The
Virtual Hospital” Trial
Recruited non-stable COPD patients
Ringbaek, T., 2015
Effect of telehealthcare on exacerbations and
hospital admissions in COPD: A randomised
controlled trial
No physiological variation reported and not
for predicting exacerbation
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